Medicilon’s IND Application Platform

Medicilon’s IND application service platform has an in-depth understanding of the regulatory and policy environment of China and the United States and its technical requirements for chemical drugs. It can provide domestic customers with CFDA IND declaration and USFDA IND/ANDA declaration services; it can provide foreign customers with CFDA IND /ANDA declaration service.

The service targets of Medicilon’s IND application platform include not only clients who do a complete set of preclinical research on Medicilon, but also pharmaceutical industry counterparts who require separate registration and declaration. The details are as follows:

Medicilon IND Application Service:

◇ Preparation and submission of CFDA IND documents for domestic customers;

◇ Submission of USFDA IND/ANDA documents as an agent for domestic customers;

◇ Submission of CFDA IND/ANDA documents as an agent for foreign clients;

◇ Provide project management services (limited to clients who provide preclinical research services by Medicilon);

◇ Review, sort out and technical evaluation of the IND/ANDA application documents provided by the customer; and then complete the compilation, review, editing and finalization.

Before submitting the application materials, Medicilon’s registration department will organize an internal technical communication meeting to analyze the application items in detail; after the application materials are submitted, there will be a senior application leader who will continue to communicate with the regulatory agency and follow up the application progress in real time until the application is submitted. Done successfully. In addition, according to the analysis of domestic drug declaration data in recent years, the country’s policy of encouraging innovation has clearly appeared in drug declaration, so it is foreseeable that innovative drugs have a good development momentum in China.

Projects independently declared by Medicilon to complete the entire set of preclinical studies:

◇ 3 IND packages are accepted by USFDA;

◇ 3 IND packages are accepted by TGA;

◇ 15 IND packages have been approved by CFDA;

◇ 10 IND packages have been submitted to CFDA

The complete set of pre-clinical research and declared public projects independently completed by Medicilon:

◇ FZ016, Class 1 chemical drug, plans to apply for CFDA and USFDA IND, has obtained CFDA clinical approval in August 2016, and will apply for USFDA soon

◇ X842, a chemical drug category 1, plans to apply for CFDA, EMEA and USFDA IND. It has submitted EMEA CTA in November 2016 and CFDA IND in January 2017. It will apply for USFDA soon.

Note: The complete set of pre-clinical research includes: API production process and quality research, preparation process and quality research, efficacy, pharmacokinetics and safety evaluation

In order to avoid registration risks, Medicilon’s application service platform can customize practical registration strategies for customers, ensure timely and accurate submission of application materials, and track the review progress in time to help customers quickly complete the registration review process.

Advantages of Medicilon IND application service:

◇ Have a professional IND, ANDA research team, which can provide one-stop research, full project management and reporting services;

◇ Possess a wealth of CFDA, USFDA review expert resources, and can provide targeted technology, regulations, and reporting strategy suggestions.

The management team of Medicilon IND service platform is composed of senior experts led by vice presidents of various departments. It wholeheartedly provides one-stop services for pharmaceutical research, non-clinical research and clinical application for Chinese and American customers.

Contact Us:

Email : marketing@medicilon.com

Tel : +44 1223 981 792（Europe） +86 021 58591500

Website: https://www.medicilon.com

Related Articles:

Medicilon’s IND Filing-innovative drug research and development

IND Enabling Studies FDA

Medicilon successfully held CFDA IND seminar in Seoul, South Korea

Medicilon sponsored the seminar on new drug preclinical research and IND application strategy

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

What is Toxicokinetics?

Toxicokinetics is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms toxicokinetics , pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...

阅读全文

Shanghai Medicilon Inc.

搜索此博客